InspireMD and NAMSA to Partner on CGUARDIANS II Pivotal Clinical Trial of the CGuard Prime™ 80 cm Carotid Stent System for Use in TCAR procedures
Portfolio Pulse from
InspireMD, Inc. (Nasdaq: NSPR) is partnering with NAMSA to conduct the CGUARDIANS II pivotal clinical trial for the CGuard Prime™ 80 cm Carotid Stent System, aimed at preventing strokes related to carotid stenosis through TCAR procedures.
February 13, 2025 | 12:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
InspireMD is collaborating with NAMSA on a pivotal clinical trial for its CGuard Prime™ 80 cm Carotid Stent System, which could enhance its market position in stroke prevention technologies.
The partnership with NAMSA for a pivotal clinical trial indicates a significant step forward in the development and potential market approval of InspireMD's CGuard Prime™ 80 cm Carotid Stent System. Successful trials could lead to increased adoption in TCAR procedures, positively impacting InspireMD's market position and stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90